OREANDA-NEWS. September 08, 2015. Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces that its long term client, NovaBone Products LLC (NovaBone), has had a novel device approved by the US FDA, for use in the delivery of its collagen bone graft product MacroFORM.

NovaBone has received FDA approval for the NovaBone MacroFORM MIS Delivery System designed for minimally invasive orthopedic procedures.  The system was developed for surgeons requiring controlled and precise delivery of collagen bone grafting material to surgical sites that aren't readily accessible. NovaBone's MacroFORM technology allows the delivery of bone marrow aspirate and other bioactive formulations to a graft in a ready to use, minimally invasive cannula.  

NovaBone has introduced six new collagen products in the last 12 months for use in the wound care and bone graft markets based on the Company's novel regenerative medicine technology and core competencies in designing innovative and cost-effective medical devices. These products use medical grade collagen supplied by Collagen Solutions plc.

Commenting on the approval Stewart White, CEO of Collagen Solutions, said: "Once again, we see the long-term value generation that we can gain by having our collagen embedded into novel products. This impressive innovation by the team at NovaBone around making their collagen products easier to use ensures a commitment to growth of these products within attractive addressable markets.  It is anticipated this regulatory approval for NovaBone will have a direct effect on revenues to Collagen Solutions."

Art Wotiz, President of NovaBone Products said "We continue to reach milestones we have established.  Our team has done an excellent job in terms of both design and manufacturing of collagen products and creating a robust pipeline of products that harness the natural healing process of the body."